BCL2L2 and acute myeloid leukemia: The BH3-mimetic navitoclax, which inhibits BCL2L1 along with BCL2 and BCL2L2 (BCL2 like 2; also known as BCLW), potently sensitized the two resistant M6 AML TF-1 and Hel to UNBS1450.